BSE: GLAXO - GlaxoSmithKline Pharmaceuticals Limited

Rentabilité sur six mois: -20.42%

Calendrier des promotions GlaxoSmithKline Pharmaceuticals Limited


À propos de l'entreprise

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally.

plus de détails
The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

ISIN INE159A01016
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 1.17
Дивиденд ао 44
Сайт https://india-pharma.gsk.com
Цена ао 2090.2
Changement de prix par jour: -0.5741% (2090.2)
Changement de prix par semaine: -6.81% (2230.1)
Changement de prix par mois: -7.82% (2254.45)
Changement de prix sur 3 mois: -23.29% (2709.15)
Changement de prix sur six mois: -20.42% (2611.55)
Changement de prix par an: -7.96% (2257.95)
Evolution du prix sur 3 ans: +20.52% (1724.3)
Evolution du prix sur 5 ans: +24.59% (1668)
Evolution des prix sur 10 ans: 0% (2078.2)
Evolution des prix depuis le début de l'année: -8.23% (2264.65)

Sous-estimation

Nom Signification Grade
P/S 9.66 1
P/BV 18.71 1
P/E 56.38 2
EV/EBITDA 24.13 5
Total: 4.5

Efficacité

Nom Signification Grade
ROA, % 17.14 5
ROE, % 33.53 9
Total: 4.5

Dividendes

Nom Signification Grade
Div yield, % 1.8 4.5
DSI 0.8571 8.57
Total: 3.95

Devoir

Nom Signification Grade
Debt/EBITDA 0.0172 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 6.74 1
Rentabilité Ebitda, % 23.53 4
Rentabilité EPS, % 11.29 2
Total: 5

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Bhushan Akshikar MD & Executive Director 32.37M
Mr. Juby Chandy Whole-Time Director & CFO 54.12M 1977 (48 années)
Mr. Amit G. Pandey Executive Vice President of Legal N/A
Ms. Simrat Sohal Vice President of Ethics & Compliance N/A
Mr. Chinmay Sharma Executive Vice President of Human Resources N/A
Ms. Sukanya Choudhary Executive Vice-President of Regulatory Affairs N/A
Ms. Aparajita Rajput Vice President of Technology
Mr. Ajay Avinash Nadkarni VP of Administration & Real Estate and Company Secretary
Mr. Ransom D'Souza Executive Vice President of Communications & Government Affairs
Mr. Shourov Mukherjee Executive Vice-President of Adult Vaccines

Adresse: India, Mumbai, GSK House - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://india-pharma.gsk.com